Hims & Hers Health, Inc. Class A Common Stock (HIMS)
44.39
-1.07 (-2.35%)
NYSE · Last Trade: Nov 3rd, 9:20 PM EST
Detailed Quote
Previous Close
45.46
Open
46.90
Bid
46.87
Ask
46.93
Day's Range
44.01 - 47.15
52 Week Range
19.15 - 72.98
Volume
40,539,934
Market Cap
8.52B
PE Ratio (TTM)
56.19
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
28,740,183
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of renewed discussions with Novo Nordisk A/S (NYSE: NVO) regarding the potential distribution of Wegovy. While the telehealth platform reported a
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 49.2% year on year to $599 million. On the other hand, next quarter’s revenue guidance of $615 million was less impressive, coming in 2.6% below analysts’ estimates. Its GAAP profit of $0.06 per share was 43.7% below analysts’ consensus estimates.
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.4% in the afternoon session after JPMorgan Chase & Co. disclosed in a regulatory filing that it had taken a significant passive stake in the company.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
The U.S. stock market has staged a remarkable recovery in October 2025, with major indices reclaiming lost ground amidst a confluence of positive corporate earnings and improving macroeconomic sentiment. However, a significant driver behind this upward trajectory isn't just institutional buying; it's a dramatic surge in heavily-shorted stocks, igniting
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.9% in the morning session after investors looked past a recent insider stock sale and focused on the company's strong growth outlook.
Shares of Hims & Hers Health are trading lower Friday morning after comments from President Donald Trump indicated that he expects the prices of popular weight-loss drugs to decrease.
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.
